Edwards’ drug/device combo
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences will integrate the EW-A-401 peripheral artery disease therapy with a catheter delivery system upon completion of an investigational new drug trial to evaluate efficacy of the compound, the firm clarifies Sept. 7 (1"The Gray Sheet" Sept. 6, 2004, p. 13). The catheter, which will treat cardiac ischemia, marks the firm's first drug/device combo product...